Acquired Company
XOMA completed its tender offer to acquire Kinnate Biopharma Inc. for $2.5879 per share in cash plus one contingent value right, with closing of the offer on April 3, 2024.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$2.65
Open
$2.65
Volume
N/A
Day Range
$2.65 - $2.65
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.16%
Institutional Own.
82.58%
Qtr Updated
03/31/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Phase 1 Update | ||
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Update | |
Exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma | Phase 1 Update |